Syneos Health ((SYNH)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
In a recent clinical study update, Syneos Health, in collaboration with GATT Technologies BV, has completed a pivotal investigation titled A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of GATT-Patch Versus TachoSil for Hemostasis During Open Liver Surgery. The study aimed to assess the safety and performance of the GATT-Patch, now named ETHIZIA, compared to TachoSil in managing bleeding during elective open liver surgeries. This study is significant as it seeks to provide a new solution for controlling surgical bleeding, potentially improving patient outcomes.
The interventions tested in this study include the GATT-Patch (ETHIZIA), an experimental hemostatic patch designed to aid in surgical bleeding control, and TachoSil, an active comparator known for its fibrin sealant properties. Both are intended to assist in managing bleeding when traditional methods are insufficient.
The study followed an interventional design with randomized allocation and a parallel intervention model. Participants were blinded to the treatment they received, ensuring unbiased results. The primary purpose was to evaluate treatment efficacy.
The study began on August 4, 2022, and was completed with the last update submitted on August 18, 2025. These dates are crucial as they mark the timeline of the study’s progression and its recent completion, providing a basis for future developments and potential market entry.
This update could influence Syneos Health’s stock performance positively, as successful study outcomes might enhance investor confidence and market positioning. With competitors in the hemostatic patch market, such advancements could shift industry dynamics, potentially benefiting Syneos Health and its collaborators.
The study is now completed, with further details available on the ClinicalTrials portal.